MedTrace Logo

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

NCT06191848 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2025-04-30

No results posted yet for this study

Summary

This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.

Conditions

Interventions

DRUG

Tirzepatide

Participants will receive tirzepatide subcutaneously

DRUG

Placebo

Participants will receive placebo subcutaneously

Sponsors & Collaborators

Principal Investigators

  • Michelle M Dowsey · University of Melbourne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-19
Primary Completion
2027-05-31
Completion
2037-05-31
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06191848 on ClinicalTrials.gov